A Phase 1 Study of RP-1664 in People With Advanced Solid Tumors With Certain Genetic Changes

Full Title

Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-1664 in Participants with Advanced Solid Tumors

Purpose

Researchers want to find the best dose of RP-1664 to treat advanced solid tumors with certain genetic mutations (changes). RP-1664 blocks a protein called PLK4, which is involved in cancer cell growth. The genetic mutation in your cancer may affect how your cancer responds to RP-1664. This drug is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have an advanced solid tumor that keeps growing even with standard therapy or for which no standard therapy exists.
• Have recovered from the serious side effects of prior treatments before taking RP-1664.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 12 or older.

Contact

For more information or to see if you can join this study, please call Dr. Ezra Rosen’s office at 646-888-4226.